Yuandong Bio-Pharmaceutical

Chengdu Yuandong Bio-Pharmaceutical Joint-Stock Co., Ltd. is a high-tech enterprise driven by R&D and innovation, integrating the R&D, production, and sales of chemical APIs, high-end chemical drugs, and biological drugs. Founded in 2009, the company has 7 wholly-owned subsidiaries and currently employs over 1,400 people. The company was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange in September 2020 (Stock Short Name: Yuandong Bio-Pharmaceutical, Stock Code: 688513).
Yuandong Bio-Pharmaceutical has always adhered to the corporate mission of "Patient-centered, bringing sunshine to human health," and through continuous technological innovation, has gradually established R&D technology and industrialization platforms that meet domestic and international standards. The company strategically focuses on the anesthesia and analgesia field while also covering major disease areas such as cardiovascular and cerebrovascular diseases, oncology, pediatric drugs, and endocrinology. It has successfully industrialized over 30 chemical drug formulation products and over 20 chemical API products. Among the marketed formulation products, 5 are the first generic drugs in China, 24 have passed consistency evaluation, and 9 products have been selected for national centralized drug procurement. Among the company's API products, over 10 chemical APIs have been exported to the international market.
Driven by R&D and innovation, Yuandong Bio-Pharmaceutical has consistently maintained a high proportion of R&D investment to build core R&D competitiveness (average R&D investment over the past three years: 20%). The company's R&D center has established multiple research platforms, including the National Enterprise Technology Center, Postdoctoral Research Station, and Sichuan Provincial Drug Solid-State Engineering Technology Research Center. It has built key technology platforms such as drug crystal form technology, sustained and controlled release technology, special drug technology, innovative drug technology, and clinical trial platforms. The company possesses six major core technologies, including drug crystal form integrated innovation and industrialization technology, innovative compound structure design, synthesis and evaluation integration technology, sustained and controlled release technology and delayed release technology, nasal spray drug delivery technology, preparation process design and lean control technology, and mRNA raw material synthesis technology. The company has assembled a diversified, internationalized, and professional R&D team. With its core R&D strength, the company has led 2 National Key R&D Projects and 5 National Major New Drug Innovation Projects, cumulatively undertaken over 50 national and provincial/ministerial projects, and obtained nearly 100 authorized domestic and international invention patents, including 15 international patents. In its focus areas, Yuandong Bio-Pharmaceutical has laid out over 60 R&D projects with a global perspective, with innovative drug projects accounting for approximately 16%. Five innovative drug projects are currently undergoing Phase I to Phase III clinical trials. Additionally, multiple ANDA high-end formulation varieties have been laid out, with 2 high-end injection projects accepted by the FDA.
Yuandong Bio-Pharmaceutical has established a mature and comprehensive marketing system with a nationwide marketing network and a professional academic promotion team, ensuring sustained growth in the company's sales scale.
Yuandong Bio-Pharmaceutical attaches great importance to quality control. Its APIs have passed FDA on-site inspections, EU certification, and audits from multiple customers in the United States and Japan. The internationalized R&D and production base - Shuode Pharmaceutical, built in accordance with NMPA, EMEA, and FDA regulatory requirements, has obtained the "Drug Manufacturing License" for multiple production lines.
Yuandong Bio-Pharmaceutical has received honors such as "National Technology Innovation Demonstration Enterprise," "National Green Factory," "National Intellectual Property Demonstration Enterprise," "Outstanding Enterprise in the Pharmaceutical Industry for the 70th Anniversary of the Founding of New China," "China Pharmaceutical R&D Product Line Industrial Enterprise," "China Pharmaceutical Industry Growth Enterprise," and "Sichuan Provincial Science and Technology Progress Second Prize." It has also ranked on lists such as "Top 100 China Pharmaceutical Innovation Enterprises," "Top 20 China Chemical Drug R&D Strength," "Top 50 China Drug R&D Comprehensive Strength," "Top 100 China Chemical Drug Enterprises," and "Top 100 STAR Market Listed Companies."
Yuandong Bio-Pharmaceutical always upholds the values of "Sunshine, Value, Innovation, and Efficiency," with the vision of "Serving the public, achieving self-fulfillment, and becoming the most respected and trusted pharmaceutical enterprise." The company aspires to become a global leader in the anesthesia and analgesia field. In the future, the company will accelerate the implementation of technological innovation and internationalization strategies, adhere to the strategic path of focusing on small molecule innovative drugs and developing biological drugs, take meeting clinical needs as its responsibility, provide patients with more, safer, and more effective high-end chemical and biological drugs, and bring sunshine to human health.